MDG_LOGO_2016_GRAY_RGB.jpg
Medigene to Present at the Cell and Gene Therapy In-Depth Focus Summit 2024
June 21, 2024 04:30 ET | Medigene AG
Planegg/Martinsried, June 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumors
June 20, 2024 08:00 ET | Medigene AG
Planegg/Martinsried, June 20, 2024. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
May 28, 2024 03:00 ET | Medigene AG
Planegg/Martinsried, May 28, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
May 21, 2024 04:00 ET | Medigene AG
Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated T...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
May 15, 2024 09:00 ET | Medigene AG
Planegg/Martinsried, May 15, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
May 14, 2024 07:30 ET | Medigene AG
Cash runway extended into July 2025 from previously April 2025Capital raise strengthens Medigene’s financial positionLead program, MDG1015, on track for IND filing in 3Q 2024 and CTA filing in 4Q...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene to Present at Upcoming Conferences
May 07, 2024 09:00 ET | Medigene AG
Planegg/Martinsried, May 7, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
May 02, 2024 04:30 ET | Medigene AG
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
May 02, 2024 02:30 ET | Medigene AG
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG reports Financial Results and Business Update for Q1 2024
April 26, 2024 03:00 ET | Medigene AG
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...